140 related articles for article (PubMed ID: 16489039)
1. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Hazlehurst LA; Argilagos RF; Emmons M; Boulware D; Beam CA; Sullivan DM; Dalton WS
Cancer Res; 2006 Feb; 66(4):2338-45. PubMed ID: 16489039
[TBL] [Abstract][Full Text] [Related]
2. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
4. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
5. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
6. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Hazlehurst LA; Valkov N; Wisner L; Storey JA; Boulware D; Sullivan DM; Dalton WS
Blood; 2001 Sep; 98(6):1897-903. PubMed ID: 11535527
[TBL] [Abstract][Full Text] [Related]
7. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Lage H; Dietel M
J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
[TBL] [Abstract][Full Text] [Related]
8. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
9. The association of up-regulation of X-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in U937 cells.
Wang X; Wang C; Qin YW; Yan SK; Gao YR
Hematol Oncol; 2008 Mar; 26(1):21-6. PubMed ID: 17721914
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
[TBL] [Abstract][Full Text] [Related]
11. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
Hazlehurst LA; Foley NE; Gleason-Guzman MC; Hacker MP; Cress AE; Greenberger LW; De Jong MC; Dalton WS
Cancer Res; 1999 Mar; 59(5):1021-8. PubMed ID: 10070958
[TBL] [Abstract][Full Text] [Related]
12. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
13. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
14. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Lage H; Helmbach H; Dietel M; Schadendorf D
Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
17. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage.
Smith PJ; Sykes HR; Fox ME; Furlong IJ
Cancer Res; 1992 Jul; 52(14):4000-8. PubMed ID: 1617677
[TBL] [Abstract][Full Text] [Related]
18. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Gray MD; Mann M; Nitiss JL; Hendershot LM
Mol Pharmacol; 2005 Dec; 68(6):1699-707. PubMed ID: 16141312
[TBL] [Abstract][Full Text] [Related]
19. Chromosome mediated gene transfer of drug resistance to mitoxantrone.
Hazlehurst LA; Gros P; Dalton WS
Anticancer Res; 1998; 18(2A):1005-10. PubMed ID: 9615755
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
